|20.94||-1.28||-5.76%||Vol 2.29M||1Y Perf 23.31%|
|Jun 28th, 2022 16:00 DELAYED|
|- -||0.02 0.10%|
|Target Price||28.09||Analyst Rating||Strong Buy 1.50|
|Potential %||34.15||Finscreener Ranking||★★★★★ 58.72|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★+ 57.97|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 75.66|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||68.86||Earnings Rating||Strong Buy|
|Market Cap||6.72B||Earnings Date||4th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Aug 2022|
|Estimated EPS Next Report||0.21|
|EPS Growth Next 5 Years %||37.30|
|Avg. Weekly Volume||2.62M|
|Avg. Monthly Volume||2.56M|
|Avg. Quarterly Volume||2.54M|
Exelixis Inc. (NASDAQ: EXEL) stock closed at 22.22 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 1.82M shares and market capitalization of 6.72B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 773 people. Exelixis Inc. CEO is Michael M. Morrissey.
The one-year performance of Exelixis Inc. stock is 23.31%, while year-to-date (YTD) performance is 21.55%. EXEL stock has a five-year performance of -7.49%. Its 52-week range is between 15.5 and 23.4, which gives EXEL stock a 52-week price range ratio of 68.86%
Exelixis Inc. currently has a PE ratio of 23.90, a price-to-book (PB) ratio of 3.11, a price-to-sale (PS) ratio of 4.69, a price to cashflow ratio of 14.10, a PEG ratio of 2.32, a ROA of 12.62%, a ROC of 13.59% and a ROE of 14.54%. The company’s profit margin is 19.51%, its EBITDA margin is 25.60%, and its revenue ttm is $1.52 Billion , which makes it $4.74 revenue per share.
Of the last four earnings reports from Exelixis Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.21 for the next earnings report. Exelixis Inc.’s next earnings report date is 04th Aug 2022.
The consensus rating of Wall Street analysts for Exelixis Inc. is Strong Buy (1.5), with a target price of $28.09, which is +34.15% compared to the current price. The earnings rating for Exelixis Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Exelixis Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Exelixis Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 6.35, ATR14 : 0.79, CCI20 : 216.28, Chaikin Money Flow : 0.35, MACD : 0.40, Money Flow Index : 74.57, ROC : 15.61, RSI : 69.79, STOCH (14,3) : 95.48, STOCH RSI : 1.00, UO : 73.44, Williams %R : -4.52), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Exelixis Inc. in the last 12-months were: Alan M. Garber (Option Excercise at a value of $125 200), Alan M. Garber (Sold 21 301 shares of value $447 321 ), Carl B. Feldbaum (Option Excercise at a value of $125 200), Carl B. Feldbaum (Sold 40 000 shares of value $742 200 ), Charles Cohen (Option Excercise at a value of $252 000), Christopher J. Senner (Option Excercise at a value of $329 400), Gisela M. Schwab (Option Excercise at a value of $168 000), Jack L. Wyszomierski (Option Excercise at a value of $125 200), Jack L. Wyszomierski (Sold 6 696 shares of value $154 008 ), Jeffrey J. Hessekiel (Sold 82 234 shares of value $1 737 455 ), Patrick J. Haley (Option Excercise at a value of $124 200), Patrick J. Haley (Sold 70 050 shares of value $1 406 945 ), Peter Lamb (Option Excercise at a value of $399 475), Peter Lamb (Sold 102 500 shares of value $1 873 475 ), Stelios Papadopoulos (Sold 84 515 shares of value $1 653 113 )
Mon, 23 May 2022 12:38 GMT Exelixis (EXEL) Gets a Buy Rating from Jefferies- TipRanks. All rights reserved.
Wed, 19 Jan 2022 11:22 GMT Exelixis (EXEL) Gets a Buy Rating from H.C. Wainwright- TipRanks. All rights reserved.
Wed, 05 Jan 2022 16:26 GMT Exelixis (EXEL) Receives a Buy from H.C. Wainwright- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.